JP Morgan Put 165 CHKP 15.11.2024/ DE000JK267H8 /
| 2024-06-04 8:58:57 AM | Chg.+0.02 | Bid9:46:19 AM | Ask9:46:19 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.48EUR | +1.37% | 1.47 Bid Size: 2,000 |
1.57 Ask Size: 2,000 |
Check Point Software... | 165.00 USD | 2024-11-15 | Put |
GlobeNewswire
1:08 AM
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
06-03
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
06-03
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
GlobeNewswire
06-03
DEADLINE ALERT for CKPT, OCGN, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class...
GlobeNewswire
06-03
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ch...
GlobeNewswire
06-03
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
GlobeNewswire
06-03
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
06-03
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet...
GlobeNewswire
06-02
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1...
GlobeNewswire
06-02
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire
06-01
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
06-01
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
06-01
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
06-01
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonst...
GlobeNewswire
06-01
CHECKPOINT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit...
GlobeNewswire
05-31
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire
05-31
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Agains...
GlobeNewswire
05-31
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response w...
GlobeNewswire
05-30
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
GlobeNewswire
05-30
Holzer & Holzer, LLC Reminds Shareholders of June 4, 2024 Lead Plaintiff Deadline in Checkpoint Ther...
GlobeNewswire
05-30
ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Befo...
